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Abstract 17 
Objectives The objective of this review is to provide an overview of PK/PD models, focusing on drug-specific 18 
PK/PD models and highlighting their value-added in drug development and regulatory decision-making. 19 
Key findings Many PK/PD models, with varying degrees of complexity and physiological understanding, have 20 
been developed to evaluate the safety and efficacy of drug products. In special populations (e.g. pediatrics), in 21 
cases where there is genetic polymorphism and in other instances where therapeutic outcomes are not well 22 
described solely by PK metrics, the implementation of PK/PD models is crucial to assure the desired clinical 23 
outcome. Since dissociation between the pharmacokinetic and pharmacodynamic profiles is often observed, it 24 
is proposed that physiologically-based pharmacokinetic (PBPK) and PK/PD models be given more weight by 25 
regulatory authorities when assessing the therapeutic equivalence of drug products. 26 
Summary Modeling and simulation approaches already play an important role in drug development. While slowly 27 
moving away from “one-size fits all” PK methodologies to assess therapeutic outcomes, further work is required 28 
to increase confidence in PK/PD models in translatability and prediction of various clinical scenarios to encourage 29 
more widespread implementation in regulatory decision-making.  30 
 31 
 32 
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1 Introduction 62 
 63 
Over the last decades pharmacokinetic/pharmacodynamics (PK/PD) models have been evolving 64 
rapidly, starting with the pioneering work in the 1960s, then moving from empirical descriptions to 65 
models based on mechanistic and physiological approaches and still evolving today in the form of 66 
state-of-the-art mathematical models describing the progression of diseases as well as entire biological 67 
systems, under the umbrella of systems pharmacology and computational biology. [1],[2],[3],[4],[5],[6],[7]  68 
At the beginning of the conjunction of pharmacokinetics with pharmacodynamics, empirical models 69 
which were based on the shape of the effect-concentration curve and assumed that the pharmacologic 70 
response is directly related to the drug plasma concentration were introduced. Soon it was recognized 71 
that this scenario is only valid when the equilibrium between the plasma and the site of action is 72 
instantaneous, when the free drug concentration and the distribution to all tissues is the same (or 73 
remains proportionally the same) and when the system is at steady-state. A variety of these so-called 74 
steady-state empirical direct effect models have been reported in the literature: linear, power, 75 
hyperbolic, sigmoid (Emax model), logarithmic and logistic. Even though these models have been applied 76 
in a number of situations,[1],[8],[9] they have two important limitations. First and most important, they 77 
are time-independent (also referred to as static models). Second, they lack a mechanistic and/or 78 
physiological understanding of the underlying pharmacokinetics and pharmacodynamics.[10] For these 79 
reasons, non-steady state, mechanistic and physiologically based modeling approaches were 80 
introduced and these are more widely used these days in drug development. 81 
In parallel to the developments in modeling approaches, major regulatory authorities have been 82 
moving slowly but surely from “one-size fits all” concepts to a more case-by-case, scientifically justified 83 
approach, in which the application of modeling and simulation (M&S) is playing a valuable supporting 84 
role. Physiologically-based pharmacokinetic (PBPK) and PK/PD models have already been implemented 85 
in the assessment of drug-drug interactions (DDIs) and extrapolation of results from adults to pediatric 86 
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populations. [11],[12],[13],[14],[15],[16] In addition, generic dermatologic and inhalation products have been 87 
approved based on pharmacodynamic or clinical endpoint bioequivalence studies (BE).[17],[18]  88 
Most recently, pharmacokinetic metrics providing information about delivery of the drug to the body 89 
and exposure (i.e. onset and duration of action),[19] such as partial areas under the concentration-time 90 
curve (pAUCs) have been recommended by the US-FDA for the evaluation of several complex oral 91 
products combining immediate (IR) with extended release (ER). [20],[21],[22] However, there are still many 92 
cases, especially for systematically acting drugs, where the value of modeling and simulation methods 93 
has not yet been widely recognized by the regulatory authorities. Such cases include the virtual 94 
bioequivalence of oral drug products, the justification for potential extension of BCS-based biowaivers 95 
to some BCS class II compounds and the reduction of the number of volunteers for bioequivalence 96 
studies of highly variable drugs (HVDs). In view of the fact that single point pharmacokinetic metrics 97 
(i.e. Cmax, AUC) used to assess bioequivalence do not always comprise an appropriate surrogate for 98 
therapeutic equivalence (TE), which by definition is the ultimate goal of bioequivalence studies,[23] it 99 
would seem appropriate to implement modeling and simulation approaches to assure therapeutic 100 
outcomes in this arena too. 101 
The aim of this review is to provide an overview of existing non-steady state PK/PD models, focusing 102 
on drug-specific case examples. These are intended to serve as examples of the importance of 103 
mechanistic PK/PD models in assuring desired therapeutic outcomes in clinical practice and to 104 
encourage wider implementation of PK/PD in support of regulatory decision-making. 105 
2 coThe effect compartment model 106 
 107 
2.1 Overview 108 
 109 
In many cases, the site of action of a drug is kinetically distinct from plasma and the equilibration 110 
between the plasma and the effect site is often rather slow. In such cases, there will be a temporal 111 
delay between the drug plasma (Cp) and effect site concentrations (Ce) and the effect will be a function 112 
6 
 
of Ce rather than of Cp. Even though bioanalytical methods have improved greatly over the last 113 
decades, measuring the concentration at the effect site often remains a challenge, due to the lack of 114 
tissue accessibility.  115 
In 1970, a hypothetical compartment serving as a link between the pharmacokinetic and 116 
pharmacodynamic models to address the equilibration kinetics was introduced by Segre et al.[2] and 117 
was applied for the first time by Forester et al.[24] to describe the time-course of effect of various 118 
cardiac glycosides.[25] This approach, using a so-called «effect compartment» or «biophase 119 
distribution» model (Fig. 1), was further elaborated and described mathematically by Holford and 120 
Sheiner [3],[26] as follows: 121 
𝑑𝐴𝑒
𝑑𝑡
= 𝑘1𝑒 · 𝐴𝑝 − 𝑘𝑒0 · 𝐴𝑒     (1) 122 
Where 𝐴𝑝 and 𝐴𝑒 are the amounts of drug in the plasma (main compartment) and in the effect 123 
compartment, respectively, and 𝑘1𝑒, 𝑘𝑒0 are the first-order rate constants for distribution and 124 
elimination from the hypothetical compartment, respectively. 125 
Assuming that the effect compartment receives a negligible amount of drug and that distribution to 126 
and clearance from the biophase compartment are equal, the model can be simplified and then 127 
coupled with a pharmacodynamic model, for example a sigmoid Emax model:  128 
𝑘1𝑒 · 𝑉𝑝 = 𝑘𝑒0 · 𝑉𝑒     (2) 129 
𝑑𝐶𝑒
𝑑𝑡
= 𝑘𝑒0 · (𝐶𝑝 − 𝐶𝑒)    (3) 130 
𝐸(𝐶𝑒(𝑡)) =
𝐸𝑚𝑎𝑥 · 𝐶𝑒(𝑡)
𝛾
𝐶𝑒(𝑡)
𝛾 + 𝐸𝐶𝑒50
𝛾      (4) 131 
where 𝐶𝑝, 𝑉𝑝, 𝐶𝑒, 𝑉𝑒 are the concentration and the volume in the central and effect compartment 132 
respectively; 𝐸𝑚𝑎𝑥, 𝐸𝐶𝑒50 and 𝛾 represent the maximum effect, the concentration in the effect site 133 
required to reach 50% of the maximum effect and the sigmoidicity factor, respectively. Alternatively, 134 
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the hypothetical compartment could be coupled with a peripheral compartment instead of the central 135 
compartment. However, it is not very common to use samples obtained at the effect site (e.g. using 136 
microdialysis) or any other peripheral compartment as a pharmacokinetic surrogate. 137 
A hallmark of the effect compartment model is the hysteresis observed in the effect-concentration 138 
plot due to the time delay between pharmacokinetics and pharmacodynamics. In fact, this is a common 139 
attribute of non-steady-state pharmacokinetic/pharmacodynamic models.[27] Well-known examples of 140 
drugs exhibiting a biophase distribution delay related response include neuromuscular blocking agents 141 
such as d-tubocurarine (see section 2.2) and pancuronium,[28] the calcium channel blocker 142 
verapamil,[29] and the bronchodilator theophylline.[30] Further cases that have been reported in the 143 
literature include quinidine, disopyramide, opioids such as pethidine, morphine, fentanyl, diclofenac, 144 
organic nitrates, benzodiazepines and digoxin.[31],[32],[33],[34],[35],[36],[37],[38] In the following section, the 145 
models for tubocurare, pancuronium, ibuprofen and morphine are used to illustrate application of the 146 
effect compartment model.  147 
2.2 Applications and case examples 148 
 149 
2.2.1 d-tubocurarine and pancuronium 150 
 151 
The assumption of a direct relationship between pharmacokinetics and drug response has been 152 
questioned for more than half a century, as illustrated by the case of d-tubocurarine.  153 
Already in the early 1960s, the first attempts to simultaneously model pharmacokinetics and 154 
pharmacodynamics, based on the available plasma concentration and effect data for d-tubocurarine, 155 
were made. In 1964, Levy implemented a log-linear model to describe the time course of d-156 
tubocurarine response, assuming one-compartment pharmacokinetics following intravenous bolus 157 
administration, based on the results of Ryan et al.[39] The log-linear model assumed that the effect of 158 
muscular relaxation is a linear function of the logarithm of the amount of d-tubocurarine present in 159 
the plasma,while elimination of the amount of d-tubocurarine in the body occurs exponentially with 160 
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time. In such cases, the pharmacologic activity declines linearly with time.[1] In 1972, an open three-161 
compartment model for the pharmacological effect of d-tubocurarine was proposed by Gibaldi et al.[40] 162 
The amount of drug in the central compartment at the time of recovery from neuromuscular block was 163 
deemed by these authors to be dose-independent. This observation, combined with the very rapid 164 
onset of action of d-tubocurarine, led the authors to the conclusion that the site of action is located in 165 
the central compartment,[40] implying instantaneous equilibration between plasma concentration and 166 
response. However, the data on which this model was based had been collected during the terminal 167 
elimination phase, during which a pseudo-equilibrium between plasma and tissues concentration is 168 
reached and the distributional delay is minimized.  169 
By contrast, Hull et al.[41] showed that after administration of pancuronium, a similar to d-tubocurarine 170 
neuromuscular blocking agent, a linear relationship between the logarithm of concentration and the 171 
response is a poor predictor of the early phase response, in which a hysteresis between the 172 
concentration in any compartment and twitch depression is observed. By adding a biophase 173 
compartment, expressed similarly to equation (3), and assuming that same degree of paralysis (i.e. 174 
during onset and offset of action) is associated with the same Ce, they were able to empirically relate 175 
the intensity of pharmacologic effect to the concentration at the site of action at every time point using 176 
a fixed effect pharmacodynamic model.[41] In the case of d-tubocurarine, the effect compartment 177 
model,  as described mathematically by Holford and Sheiner,[3],[26] was successfully applied as well. 178 
Plasma concentration and effect data after intravenous administration were analyzed from healthy 179 
subjects and patients with renal failure. The model was able to fit data from both groups without 180 
statistically significant differences in the pharmacokinetic or pharmacodynamic parameters between 181 
the two groups.[42] Interestingly, the equilibration half-life (4 minutes) for pancuronium estimated in a 182 
more empirical way by Hull et al.[41] was very similar to the one for d-tubocurarine reported by Sheiner 183 
et al.[42] using an explicit pharmacokinetic/pharmacodynamic model. 184 
In parallel, Stanski et al.[43] explored the influence of various anesthetic agents on the muscle-relaxing 185 
effect of d-tubocurarine. Halothane induced-anesthesia, in comparison to anesthesia with morphine 186 
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and nitrous oxide, prolonged the equilibration half-life. An open two-compartment pharmacokinetic 187 
model coupled with a hypothetical effect compartment was implemented to fit both plasma and 188 
muscle paralysis data. Interestingly, changes in pharmacodynamic (ke0, t1/2ke0, EC50), but not in 189 
pharmacokinetic, parameters were observed for patients under halothane anesthesia. Furthermore, it 190 
was possible to distinguish between the effects of the agents on the EC50 for muscle paralysis showing 191 
that halothane sensitizes the neuromuscular junction to d-tubocurarine. Provided that the diffusion of 192 
tubocurarine into the extracellular fluid of the muscle and the receptor affinity is high, the rate limiting 193 
step for the onset of action is the rate of muscle perfusion, which is inversely proportional to the 194 
equilibration half-life (t1/2ke0).[43] Although the onset and the magnitude of response is dependent on 195 
muscle blood flow, the recovery from neuromuscular blockage is perfusion-independent and solely 196 
related to the drug-receptor dissociation rate.[44] The significant increase in t1/2ke0 under halothane-197 
induced anesthesia is consistent with the decreased muscle blood flow, which would suggest a later 198 
onset of paralysis. However, halothane also decreases the EC50, which compensates for the decrease 199 
in perfusion and results in a similar onset to that observed under morphine and nitrous oxide 200 
anesthesia.  201 
In summary, the evaluation of the pharmacodynamics in concert with the pharmacodynamics of these 202 
two muscle relaxants enabled a more mechanistic description of their dose-response characteristics 203 
and a better understanding of the drug interaction with the anaesthetic. These early successes 204 
triggered further interest in combining pharmacokinetics with pharmacodynamics to achieve a  more 205 
mechanistic description of the relationship between dose, dosing and clinical effects. 206 
2.2.2 Ibuprofen: dental pain relief 207 
 208 
Ibuprofen was selected as a model drug to investigate the clinical relevance of bioequivalence metrics 209 
to the therapeutic effect. An analysis of 25 bioequivalence studies of Ibuprofen immediate-release oral 210 
dosage forms over a  dose range from 200-600 mg showed that 14 of the studies failed to prove 211 
bioequivalence in Cmax , even though AUC fell within the bioequivalence limits.[45] The authors reported 212 
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that Ibuprofen, a weakly acidic BCS class II compound, is at higher risk to fail bioequivalence because 213 
of Cmax variations. However, in cases where the plasma concentration is related non-linearly and/or 214 
indirectly to the drug effect[46],[3] , the Cmax and tmax values may not be accurate metrics for the 215 
therapeutic response. For example, if the Cmax is higher than anticipated this will not necessarily 216 
translate to toxic effects. Likewise, if the Cmax is lower, this will not necessarily result in lack of 217 
efficacy.[47]  218 
Dissociation between pharmacokinetics and pharmacodynamics is common for NSAIDS. This may be 219 
because of delayed distribution to the biophase or related to an indirect response mechanism, for 220 
example when the pharmacodynamic endpoint is the inhibition of inflammation mediators.[48] Pain 221 
relief and antipyresis after administration of ibuprofen formulations have been extensively modelled 222 
in different populations. In this section, the main studies for pain relief after third molar extraction are 223 
presented, while studies investigating the antipyretic effect are addressed in section 4.2.1. 224 
Third molar extraction pain models describe the postoperative onset of inflammation, with maximum 225 
pain intensity occurring in 12 hours or less. Relief from pain associated with tooth extraction exhibits 226 
high reproducibility and a low placebo effect, features that are important for differentiation among 227 
various doses and thus for the identification of dose-response curves.[49],[50],[51],[52] The most commonly 228 
evaluated endpoints in dental pain models are the pain intensity difference (PID) and sum of pain 229 
intensity difference (SPID), the pain relief (PAR) and total pain relief (TOTPAR), the time to re-230 
medication (REMD), the time to first perceptible pain relief (TFPR) and time to first meaningful pain 231 
relief (TFMP).[53][54] 232 
In a double-blind, randomized, single- and multi-dose study of 254 adult patients, who had undergone 233 
third molar surgery, Hersh et al.[50] reported a positive dose-response relationship for sum pain 234 
intensity (SPID), total pain relief (TOTPAR), time to re-medication (REMD) and overall pain relief, after 235 
administration of 200 and 400 mg of ibuprofen as a single-dose. During the multi-dose phase, no 236 
significant differences between the two dose levels were detected. The authors concluded that 237 
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patients could benefit from higher doses for pain treatment immediately after the extraction, but that 238 
lower doses would be satisfactory thereafter. These results suggest that the single-dose approach 239 
adopted for bioequivalence testing might be over-discriminating for the assessment of ibuprofen 240 
formulations with regard to the maintenance of dental pain relief. Indeed, McQuay et al.[55] observed 241 
no significant differences between 200 and 400 mg of ibuprofen in a double-blind, randomized, 242 
placebo-controlled, single-dose study comparing the analgesic effect of 200 and 400 mg of ibuprofen 243 
with placebo and with 200 mg ibuprofen plus 50, 100 or 200 mg caffeine in 161 adult patients after 244 
third molar removal. In a further study, a positive dose-response relationship of ibuprofen over the 245 
dose range 50-400 mg with regard to sum of pain intensity difference (SPID) and total pain relief 246 
(TOTPAR) was reported by Schou et al.[54] However, in terms of TOTPAR the doses of 200 and 400 mg 247 
did not differ significantly.  248 
A meta-analysis of data from 13 trials with total of 994 patients reported an absolute increase of only 249 
9% (from 59% to 68%) in the number of patients who achieved at least 50% pain relief, when the dose 250 
of ibuprofen was doubled from 200 to 400 mg, meaning that 10 patients would need to be treated 251 
with the higher dose for just one of them to benefit. [56] The analysis indicates that the dose-response 252 
relationship is rather flat in the dose range 200 to 400 mg with respect dental pain relief by ibuprofen.  253 
Li et al.[53] applied a pharmacodynamic model to investigate the onset and offset of dental pain relief 254 
after administration of effervescent and standard tablets containing 400 mg ibuprofen. As an endpoint, 255 
a categorical pain relief score was applied and treated as a continuous variable, in agreement with 256 
Lemmens et al.[57] The observed distributional delay of the response to ibuprofen was addressed by 257 
the addition of an effect-compartment model and the overall effect as the sum of placebo and drug 258 
was described as following:  259 
𝑑(𝐶𝑒[𝑡])
𝑑𝑡
= 𝑘𝑒0 · {𝐶𝑝[𝑡] − 𝐶𝑒[𝑡]}     (5) 260 
𝑓𝑑(𝐶𝑒) =
𝐸𝑚𝑎𝑥 · 𝐶𝑒
𝛾
𝐶𝑒
𝛾 + 𝐸𝐶50
𝛾      (6) 261 
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𝑓𝑝[𝑡] = 𝑃𝑚𝑎𝑥 · (1 − 𝑒
−𝑘𝑝·𝑡)     (7) 262 
𝑃𝑅(𝑡) =  𝑓𝑝[𝑡] + 𝑓𝑑(𝐶𝑒) + 𝜀     (8) 263 
where 𝐶𝑝 and 𝐶𝑒 are the drug concentrations in plasma and in the effect-site compartment, 264 
respectively; 𝑘𝑒0 and 𝑘𝑝 are the first-order rate constants for the placebo effect and equilibration, 265 
respectively; 𝐸𝑚𝑎𝑥 and 𝑃𝑚𝑎𝑥 are the maximum ibuprofen and placebo effect, 𝑓𝑑(𝐶𝑒) and 𝑓𝑝[𝑡] are the 266 
pain relief by ibuprofen and placebo, respectively; γ and 𝐸𝐶50 are the sigmoidicity factor and the drug 267 
plasma concentration to achieve 50% of 𝐸𝑚𝑎𝑥, respectively; 𝑃𝑅(𝑡) represents the pain relief score at 268 
a given time t and 𝜀 stands for the normally distributed residual variability. 269 
The model was able to describe the pain relief score data adequately and the effect was directly related 270 
to the effect-site concentration, which increased much faster for the effervescent than the standard 271 
tablets, with the peak effect site-concentration occurring one hour earlier than for the standard tablet 272 
(1.0 h versus 2.0 h). The sigmoidicity factor was estimated to be 2.0 ± 0.43, confirming the relatively 273 
flat dose-response curve of ibuprofen. 274 
More recently, a PBPK/PD model for Ibuprofen was developed and validated by Cristofoletti and 275 
Dressman[58] with the SimCyp Simulator® version 12.2 (SimCyp Ltd.), fitting antipyretic and dental pain 276 
relief pharmacodynamic models to pharmacokinetic and pharmacodynamic data already published in 277 
the literature. The main goals of this study were a comprehensive evaluation of the clinical relevance 278 
of bioequivalence criteria for ibuprofen immediate-release oral dosage forms and a risk assessment of 279 
waiving in vivo bioequivalence studies of such products. To simulate the pharmacokinetic and 280 
pharmacodynamic profiles, virtual populations similar to those enrolled in the clinical studies by 281 
Walson et al.[59] and Li et al.[60] in terms of age and gender ratio were generated, such that virtual trials 282 
for the dental pain relief model included 100 adults per trial aging between 18-40 years and receiving 283 
tablets of 100, 200, 280 or 400 mg of Ibuprofen. One-at-a-time sensitivity analysis for the gastric 284 
solubility, gastric emptying time (GET), apparent permeability coefficient (Papp) and small intestine pH 285 
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was conducted and the effect of applying different dissolution rates in the simulations on the resulting 286 
pharmacokinetic and pharmacodynamic profiles was also investigated.[58] The authors found that the 287 
dose-response curve for dental pain relief is shallow and as a result relatively insensitive to changes in 288 
plasma concentrations within the range 12-23 mg/L (applying an EC50 of 10.2 mg/L). Comparing the 289 
pharmacodynamic response after the simulated administration of 280 versus 400 mg Ibuprofen tablets 290 
to adults undergoing third molar extraction, no significant differences in the response occurred. 291 
Interestingly, although (under the assumption that the 400 mg tablet is the reference product and the 292 
280 mg tablet is the test product in a virtual bioequivalence scenario) the test product would not be 293 
bioequivalent to the reference product in terms of pharmacokinetics (Cmax ratio (Cmax-T/ Cmax-R) of 0.7), 294 
the 280 mg tablet would be still considered therapeutically equivalent to the 400 mg tablet for dental 295 
pain relief in adult patients.   296 
Cristofoletti and Dressman combined in vitro in vivo extrapolation with PBPK/PD model to simulate the 297 
effect of different dissolution rates from products containing ibuprofen free acid (IBU-H) and salts (IBU 298 
salts) and to investigate whether these would a) reflect reported differences in pharmacokinetics as 299 
well as whether b) differences in pharmacokinetics would translate into difference in the ability of 300 
ibuprofen to relieve dental pain in adults.[61] The model was able to adequately predict the observed 301 
pharmacokinetic profiles. The pain relief model by Li et al.[60] was adopted to simulate ibuprofen 302 
response. As expected from the faster dissolution of the products containing salt forms of ibuprofen, 303 
the 90% confidence intervals (CI) for Cmax did not meet the average bioequivalence (ABE) acceptance 304 
criteria. However, pain relief scores elicited by ibuprofen free acid and salts were identical. 305 
Interestingly, the simulated peak effect-site concentrations for both IBU-H and IBU salts 400 mg were 306 
found to be higher than the estimated EC80≈20 mg/L, indicating that the extent of pain relief would be 307 
insensitive to pharmacokinetic changes at this dose level. Importantly, the duration over which the 308 
effect-site concentrations are maintained above EC80 should be also taken into account. The authors 309 
concluded that the bioequivalence criteria for Cmax might be over-discriminatory and not clinically 310 
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relevant for assessing therapeutic equivalence of ibuprofen products in terms of overall dental pain 311 
relief.   312 
As illustrated by the example of ibuprofen, therapeutic equivalence is not always captured 313 
appropriately by simple plasma concentration measurements due to the insensitivity of the 314 
pharmacodynamic response to the pharmacokinetics in the dose range typically applied. From this 315 
case example, it is evident that the interaction of the drug pharmacokinetics with the pharmacologic 316 
response should be taken into account to set clinically relevant specifications (“safe spaces”) for drug 317 
products. Modeling and simulation techniques would be a powerful tool in this direction, facilitating a 318 
regulatory transition from the current “one size fits all” bioequivalence paradigm to a scenario based 319 
on the clinically-based, specific PK/PD characteristics of the drug product and thus able to provide a 320 
more accurate assessment of therapeutic equivalence. 321 
2.2.3 Anti-nociceptive effect of morphine 322 
 323 
For drugs, which exhibit high biological target affinity and/or reach their site of action by active 324 
transport mechanisms, distribution to the biophase may or may not impose a rate-limiting step. Over 325 
the past few years, several specific transporters that may influence the distribution of drugs to their 326 
site of action in the central nervous system (CNS) have been identified.[62],[63],[64],[65] However, the 327 
number of pharmacokinetic/pharmacodynamic (PK/PD) studies exploring the functional role of these 328 
transporters in the distribution to the effect site are few. One interesting example is the anti-329 
nociceptive effect of morphine, for which mechanism-based models of the biophase distribution 330 
within the central nervous system were established using intracerebral micro-dialysis. 331 
Letrent et al.[66] investigated the effect of GF120918, a potent and selective P-glycoprotein (P-gp) 332 
inhibitor, on the pharmacokinetics and pharmacodynamics of morphine in rats, which were 333 
randomized into GF120918 pretreated, vehicle and control groups. The concentrations of both 334 
morphine and its metabolite, morphine-3-glucoronide (M3G), in serum were quantified and the anti-335 
nociception was expressed as the percentage of maximum possible response (% MPR). A two-336 
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compartment pharmacokinetic model, together with an effect compartment coupled to a sigmoidal 337 
Emax model was employed to simultaneously fit the pharmacokinetic and pharmacodynamic data. 338 
Among the pharmacokinetic (AUC, Cl, MRT, Vss) and pharmacodynamic (ke0, EC50, γ) parameters 339 
evaluated, only the equilibration rate constant (ke0) and the %MPR were significantly altered by pre-340 
treatment with GF120918, indicating a faster onset and more intense action, respectively (p=0.0023). 341 
The increased pharmacodynamic response could not be attributed to pharmacokinetic changes or to 342 
the elevated M3G concentrations. Since M3G does not possess any anti-nociceptive 343 
properties,[67],[68],[69] the authors suggested that the inhibition of P-gp by GF1920918 might diminish the 344 
efflux of morphine from brain capillary endothelial cells, leading to more rapid distribution and higher 345 
concentrations of morphine at its site of action. These data were supported by Xie et al.[70], who 346 
demonstrated, using trans-cortical micro-dialysis, that morphine concentrations in the brain were 347 
increased (1.7-fold) after administration to mdr-1a genetic deficient rats, whereas the metabolite M3G 348 
was unaffected. 349 
Evaluation of the kinetics of biophase distribution within the central nervous system by intracerebral 350 
microdialysis, which has already been successfully applied to the characterization of the distributional 351 
behavior in several cases [71],[70],[72],[73], is a promising tool for the development of more sophisticated, 352 
mechanism-based models, enabling as yet unexplained aspects of the pharmacodynamics of the 353 
central nervous system acting drugs to be illuminated. 354 
 355 
3 Modeling of irreversible mechanisms of action  356 
 357 
3.1 Overview 358 
 359 
In this section, we describe some examples of drugs that act in the human body through irreversible 360 
inhibition at the site of action. In general, pharmacodynamic (PD) effects are initiated by the 361 
interaction of drugs with targets such as receptors, enzymes, ion channels, cell membranes etc. Such 362 
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interactions may be reversible, with a balance between association and dissociation of the drug with 363 
the target, or irreversible when a drug bonds covalently to the target or the dissociation rate is 364 
extremely slow for the relevant time span. As a result of these interactions, a cascade of events is 365 
triggered, leading to the pharmacological effect, which can either stimulate (agonist) or inhibit 366 
(antagonist) a physiological process.[74],[75] 367 
In many cases, drugs that irreversibly inhibit a physiological process are transformed, as a first step, 368 
into reactive metabolites, which then bind covalently to their target, resulting in its inactivation. In 369 
order for the pre-existing situation to be reestablished, it is necessary to resynthesize the target. In 370 
such cases, the duration of action is likely to be independent of the pharmacokinetic half-life of 371 
elimination of the drug and instead depends essentially on the de novo synthesis of the target. The 372 
irreversible inactivation of endogenous enzymes or receptors caused by drugs e.g. the antiplatelet 373 
effect of aspirin after binding cyclo-oxygenase-1,[76],[77] the 5 α-reductase inhibitors,[78],[79] and the 374 
proton pump inhibition by proton pump inhibitors (PPI),[80],[81],[82] are often described using  such 375 
turnover models. Further examples are drugs that  trigger apoptosis in human cells, bactericidal 376 
antibiotics,[83] reduction of viral load due to the treatment with antivirals,[84] cell death processes 377 
induced by anticancer drugs[85] and  cytotoxic drugs which cause myelosupression.[86] 378 
In general, the turnover models that have been presented in the literature are based on the following 379 
differential equation:[87]  380 
𝑑𝑅
𝑑𝑡
= 𝑘𝑖𝑛 − 𝑘𝑜𝑢𝑡 · 𝑅 − 𝑓(𝐶) · 𝑅                𝑅(0) = 𝑅0  (9)     381 
where R denotes the response produced by the drug, 𝑅0 is its initial response value, 𝑘𝑖𝑛 is a zero-order 382 
rate constant for the response, 𝑘𝑜𝑢𝑡 is a first-order elimination rate constant and the function of the 383 
drug concentration 𝑓(𝐶) can be interpreted as a bimolecular interaction of the drug or its active 384 
metabolite with the target. This is the general equation representing the turnover rate of the response, 385 
however, more complex scenarios are also possible, requiring more mechanistic models to be 386 
developed as will be discussed later.   387 
 388 
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Figure 2 depicts a turnover model that can be applied to the interaction between the drugs with 389 
receptors, enzymes or ion channels. In the case of interaction with endogenous enzymes, the 𝑘𝑖𝑛 and 390 
𝑘𝑜𝑢𝑡 parameters represent apparent rates of response formation and dissipation respectively and f(C) 391 
represents the effect as a function of drug concentration. 392 
 393 
3.2 Applications and case examples 394 
 395 
3.2.1 Proton pump inhibitors 396 
 397 
Proton pump inhibitors (PPIs) were chosen as the drug model for this topic since their inhibition of the 398 
proton pump (H+, K+-ATPase) enzyme present in the parietal cells of the stomach is irreversible. To 399 
understand the mechanism of inhibition by the PPIs, models describing the turnover of H+, K+-ATPase 400 
have been described. 401 
The PPIs are, in and of themselves, inactive drugs that require an acid environment for their activation. 402 
These weakly basic substances reach the general circulation after absorption from the gastrointestinal 403 
tract and then become concentrated in the acid compartment of the parietal cells present in the gastric 404 
mucosa. Following their activation by conversion to the sulphonamide form in the acidic intracellular 405 
environment of the parietal cells, a covalent bond occurs between the activated PPI and cysteine 406 
residues present in H+, K+-ATPase. This enzyme is responsible for the final step in the secretory gastric 407 
acid process.[81],[88],[89] As a consequence of the binding, the enzyme is inactivated and this results in 408 
suppression of acid secretion into the gastric lumen.[90],[80] PPIs inhibit both basal and stimulated gastric 409 
acid secretion, regardless of the nature of stimulation of the parietal cells. In order for the acid 410 
secretion to be re-established, de novo synthesis of H+, K+-ATPase is necessary.[90],[91],[92]  411 
Even though the elimination half-life of PPIs is only 1-2 hours, the pharmacodynamic half-life of the 412 
inhibitory effect on H+, K+-ATPase is about 48 hours, rendering a rapid elimination (PK) but long 413 
duration of response (PD) to members of this class.[92],[93],[94] By comparison, the pharmacodynamics of 414 
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drugs that reversibly bind to the proton pump to decrease acidic secretion in the stomach, such as 415 
cimetidine and other H2 receptor antagonists, can be described with a direct response PD model.[95]  416 
To construct a mechanistic PK/PD model for PPIs, several factors have to be considered: the 417 
accumulation of PPI in the parietal cell, the amount of active enzymes present in the canaliculus of 418 
parietal cell, the rate of de novo synthesis of new proton pump enzymes, the metabolism and 419 
inactivation of PPIs, the extent of covalent PPI binding to the proton pump in the parietal cell and the 420 
stability of this binding.[96] Because of this complexity, several different models have been proposed to 421 
describe the relationship between PK and PD for this class of drugs. There are empirical models that 422 
simply consider the turnover of the proton pump and those that are more mechanistic, taking into 423 
account the relevant physiology and PPI characteristics. In this section we will focus on PK/PD models 424 
that have been used to describe the difference between the elimination half-life (PK) of PPIs and the 425 
temporal inhibition of acid secretion (PD) that results from binding of the PPI with H+, K+-ATPase. 426 
Katashima and co-workers[95] were the first to publish a mechanistic PK/PD model for PPIs. In the first 427 
study, a model relating the unbound plasma concentration (𝐶𝑓) of lanzoprazole and omeprazole to 428 
the inhibitory effect on stomach acid secretion was developed. This model, illustrated in Figure 3, 429 
utilizes the apparent turnover process of H+, K+-ATPase to describe the relationship between plasma 430 
concentration and the inhibitory effect of the PPIs on gastric acid secretion.[97] 431 
 432 
According to this PK/PD model, the inactive form of the PPI is present in the plasma, and only after 433 
reaching the acid environment of the parietal cells is it transformed into the active form. This form 434 
then reacts with active H+, K+-ATPase according to a second order reaction with the rate constant, 𝐾, 435 
to establish a covalent bond between the activated PPI and H+, K+-ATPase, resulting in inactivation of 436 
the enzyme. 437 
 438 
The total amount of proton pump (Et) remains at a constant level (ks/k1) because H+, K+-ATPase is 439 
synthesized, on the one hand, at a rate described by the rate constant, Ks, but also eliminated, on the 440 
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other hand, at a rate described by the first order rate constant 𝑘1. The inactive proton pump recovers 441 
at a rate described by the first order rate constant 𝑘2. Under these circumstances, the apparent 442 
turnover rate constant, k, is represented by 𝑘1 + 𝑘2. The time courses of variation in the amount of 443 
active H+, K+-ATPase (𝐸) and the inactive fraction (𝐸𝑐) are expressed by the following equations: 444 
𝑑𝐸
𝑑𝑡
=  −𝐾 ∙ 𝐶𝑓 ∙ 𝐸 − 𝑘 ∙ 𝐸 + 𝑘2 ∙ 𝐸𝑐 + 𝐾𝑠       (10)   445 
𝑑𝐸𝑐
𝑑𝑡
= 𝐾 ∙ 𝐶𝑓 ∙ 𝐸 − (𝑘1 − 𝑘2) ∙ 𝐸𝑐     (11)   446 
An in vivo pharmacokinetic and pharmacodynamic study in rats was conducted over a dose range of 447 
0.006 - 3 mg/kg (IV) with omeprazole and lanzoprazole. Using the data from intravenous 448 
administration in rats, the estimated half-life of the proton pump was 27 times longer than the 449 
elimination half-life for omeprazole and 66 times longer for lansoprazole. Using the PK/PD model 450 
described above, good agreement between predicted and observed data was achieved for both drugs. 451 
 452 
After their success with the PK/PD model in describing the data from rats, Katashima and co-workers[81] 453 
extended the model to human studies with pantoprazole (PPZ), lansoprazole (LPZ) and omeprazole 454 
(OPZ). The PK/PD analysis of these PPIs in humans was conducted using data obtained after oral 455 
administration of OPZ (40mg), LPZ (30mg) and PPZ (40mg). Again, good agreement between the 456 
predicted and observed values for the parameters was achieved. The estimated half-life of elimination 457 
for omeprazole was 0.854 h, for lansoprazole 1.66 h and for pantoprazole 1.52 h, while the apparent 458 
recovery half-life of the inhibitory effect on gastric acid secretion was 27.5 h for omeprazole, 12.9 h 459 
for lanzaprole and 49.9 h for pantaprazole. These results confirmed the divergence between plasma 460 
concentration (PK) and the inhibitory effect on gastric acid secretion (PD) of these there PPIs. 461 
 462 
The mechanistic PK/PD model was extended by Puchalski and co-workers for lansoprazole.[82] Their 463 
model was set up to describe the intra-gastric pH time profile over a 24 hour period, enabling the 464 
circadian rhythm of acid secretion and food effects on intra-gastric pH to be taken into account. Using 465 
this model, the estimated value for lansoprazole half-life of elimination was 3.2h, somewhat longer 466 
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than in the Katashima model (1.66 h), while in the clinical study the pH had not returned to the baseline 467 
level after 24h. As this proposed model took into account several factors that can interfere in the PPI 468 
absorption and activation, it should be particularly useful in the design of clinical studies, the prediction 469 
of the optimal dosing regimen and the investigation of PPI effects in different patient populations.[82] 470 
The inhibitory effect of PPIs on gastric acid secretion has also been described by Abelo and co-471 
workers[80] using a simpler, empirical turnover model type I, as introduced by Dayneka et al.[98] (see 472 
section 4.1.1). In the basic turnover model shown in Eq. 12 and applied to omeprazole in Figure 4, it is 473 
assumed that the drug inhibits or stimulates the production of an effect, which can be characterized 474 
by the zero order 𝑘𝑖𝑛 turnover and the elimination first order kout rate constants as appropriate. The 475 
rate of change of the response (R) provoked in the absence of the drug is described with the following 476 
equation: 477 
 478 
𝑑𝑅
𝑑𝑡
= 𝑘𝑖𝑛 − 𝑘𝑜𝑢𝑡 ∙ 𝑅   (12) 479 
 480 
According to Eq. 12 the acid secretion (𝐴𝑆) is directly proportional to the concentration of the active 481 
proton pump enzyme (𝐸). Equation 13 can be used to correct for the placebo effect on acid secretion: 482 
𝑅 =
𝐴𝑆(𝐷𝑟𝑢𝑔,𝑡)
𝐴𝑆(𝑃𝑙𝑎𝑐𝑒𝑏𝑜,𝑡)
=
𝐸(𝐷𝑟𝑢𝑔,𝑡)
𝐸(𝑃𝑙𝑎𝑐𝑒𝑏𝑜,𝑡)
     (13)    483 
 484 
Omeprazole irreversibly removes the enzyme from the system at a rate proportional to the amount of 485 
enzyme and the inhibitor concentration. Irreversible removal of the enzyme results in a decrease in 486 
the response according to equation 14: 487 
𝑑𝑅
𝑑𝑡
= 𝑘𝑖𝑛 − (𝑘𝑜𝑢𝑡 + 𝑘𝑜𝑚𝑒 ∙ 𝐶𝑝) ∙ 𝑅    (14)   488 
 489 
For a given concentration of omeprazole, the value for 𝑅 at steady state (𝑅𝑠𝑠) will be: 490 
𝑅𝑠𝑠 =
𝑘𝑖𝑛
𝑘𝑜𝑢𝑡+𝑘𝑜𝑚𝑒∙𝐶𝑝𝑆𝑆
     (15)  491 
This relationship states that with increasing omeprazole concentration, 𝑅𝑠𝑠 approaches zero. 492 
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Data from studies in dogs were used to predict the PK and PD parameters for omeprazole for this 493 
species, leading to a prediction for the half-life of elimination of 1.3 h and for the effective half-life for 494 
inhibition of acid secretion (t1/2 Kout) of 51h. Using allometric scaling, the predicted half-life for humans 495 
was 1.5 h and the effective half-life for inhibition of acid secretion (t1/2 Kout) was 71.7 h. The discrepancy 496 
between predicted (71.7 h) and observed (48) t1/2 Kout  in humans was attributed to differences in basal 497 
acid secretion between dogs and humans. [99] 498 
 499 
Ferron and co-workers [100] also used the basic turnover irreversible PK/PD approach, in this case to 500 
describe the inhibition of gastric acid secretion by pantoprazole in rats and humans. The model was 501 
able to adequately describe the time course of gastric acid secretion in rats at all doses studied. The 502 
next step it was to apply it to gastric secretion data obtained after single or multiple oral or intravenous 503 
administration of pantoprazole in humans. The estimated half-life for pantoprazole was 0.5 h in rats 504 
and 0.8 h in humans, in agreement with the observed data in both species. 505 
 506 
Both the mechanistic and empirical models described in this section were able to predict the 507 
discrepancy between the half-life elimination (PK) of PPIs and the time-course of inhibition of acid 508 
secretion (PD). The models were also successful in describing further characteristics of PPIs, namely 509 
that the effect in acid secretion inhibition of PPIs is linked to the extent of exposure (AUC), and that 510 
the onset of action is governed by the maximum concentration (Cmax). Thus, PK/PD modelling provides 511 
a powerful tool for analysing/predicting effects achieved with other dosing regimens. To circumvent 512 
the use of invasive methods in clinical studies for monitoring the gastric pH and inhibition of gastric 513 
acid secretion, it would be necessary to build PK/PD models that can also predict the extent of acid 514 
inhibition in terms of the pH value and the duration over which the pH is kept above a clinically relevant 515 
threshold value (usually pH 4) by the PPI. 516 
 517 
22 
 
In conclusion, modelling and simulation clearly shows why PPIs, despite having a short plasma half-life, 518 
are able to have a long duration of effect. Such models enable better decisions to be made about 519 
dosing intervals and also help to identify the time-frames over which drug/drug interactions with PPIs 520 
may persist.  521 
3.2.2 Acetylsalicylic acid 522 
 523 
Similarly to the PPIs, aspirin (ASA) has a long duration of action, even though it has a short elimination 524 
half-life (t1/2 18-30 min).[101],[102] ASA inhibits platelet-derived thromboxane (TXB2), with approximately 525 
60% inhibition still observed four days after discontinuation of ASA.[101],[102] This pronounced 526 
dissociation between the elimination half-life (PK) and the time-frame of drug action (PD) occurs 527 
because ASA binds covalently to TXB2 causing irreversible inhibition of this enzyme. The TXB2 activity 528 
can only be re-established by synthesis of new platelets, which is a process that occurs over a period 529 
of approximately 10-14 days.[101] Because platelets are not nucleated, they are unable to synthesize 530 
new COX-1, and for this reason platelet function will only normalize after the platelets that have been 531 
acetylated by ASA are removed from the systemic circulation and replaced by new platelets derived 532 
from megakaryocytes.[103] 533 
 534 
The first model describing cyclooxygenase activity in platelets and the blood vessel endothelium after 535 
oral administration of aspirin was developed by Yamamoto and co-workers.[77] These authors used 536 
irreversible inhibition, with renewal by enzymatic turnover, to explain the long duration of the 537 
antiplatelet effect of aspirin in humans. In this study thromboxane B2 concentrations and the 538 
percentage of prostacyclin production in the blood vessels were used as biomarkers.[77] 539 
 540 
It has been suggested that non-selective COX-1 inhibitors, e.g. ibuprofen, could limit the cardio-541 
protective effect of aspirin.[104] For this reason Hong and co-workers[76] developed a PK/PD model 542 
that was based on the turnover of the COX-1 enzyme, in which the irreversible inhibition  by aspirin 543 
and the reversible binding by ibuprofen were both incorporated. The rate changes of free 544 
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enzyme concentration available for aspirin binding (𝐸) and the ibuprofen-enzyme complex (𝐸𝐼) were 545 
described by the following equations:  546 
𝑑𝐸
𝑑𝑡
= 𝑘𝑖𝑛 − 𝑘𝑜𝑢𝑡 · 𝐸 − 𝐾 ∙ 𝐶𝑎𝑠𝑎 ∙ 𝐸 − 𝑘𝑜𝑛 ∙ 𝐶𝑖𝑏𝑢 ∙ 𝐸 + 𝑘𝑜𝑓𝑓 ∙ 𝐸𝐼     (16)     547 
𝑑𝐸𝐼
𝑑𝑡
= 𝑘𝑜𝑛 · 𝐶𝑖𝑏𝑢 ∙ 𝐸 − 𝑘𝑜𝑓𝑓 ∙ 𝐸𝐼 − 𝑘𝑜𝑢𝑡 ∙ 𝐸𝐼     (17)                 548 
where 𝑘𝑖𝑛 is the zero-order production effect rate constant, 𝑘𝑜𝑢𝑡 is the first order elimination rate 549 
constant, 𝐾 is the second-order rate constant for the irreversible enzyme inactivation by aspirin, 550 
and 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 are the association and dissociation rate constants for binding of ibuprofen on the 551 
enzyme. 𝐶𝑎𝑠𝑎 and  𝐶𝑖𝑏𝑢 represent the aspirin and ibuprofen concentrations in the plasma, assuming 552 
that both drugs follow a one compartment PK model with first order rate constants for absorption and 553 
elimination.  554 
The mechanistic PK/PD model was able to reflect the anti-platelet effect of aspirin administered either 555 
alone or concomitantly with ibuprofen. As well as simulating the PK and PD time courses,  significant 556 
inhibition of the antiplatelet effects of aspirin in the presence of a typical ibuprofen regimen was also 557 
demonstrated.  558 
The most mechanistic PK/PD model describing the effects of aspirin on COX-1 activity to date was 559 
proposed  by Giareta and co-workers.[105] This model uses a population of megakaryocytes (MK) and 560 
peripheral platelets present in the blood circulation to describe aspirin’s antiplatelet activity, as shown 561 
in Figure 5.  562 
For the construction of the PK/PD model for aspirin, the inactivation of COX-1 by low dose aspirin and 563 
the recovery of COX-1 after stopping treatment were taken into consideration. Other physiological 564 
processes, e.g. the description of the megacariopoiese process responsible for the maturation and 565 
generation of new platelets, were also accounted for. The basic characteristics of the megacariopoiese 566 
process are shown in Figure 5. The schematic description of the resulting PK/PD model is shown in 567 
Figure 6. It consists of three linear compartments to describe the PK behavior of aspirin and two non-568 
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linear compartments to describe the mechanism of inactivation of COX-1 (PD) in MK cells and in the 569 
platelets generated from them. A full mathematical description of the model has been published by 570 
Giaretta and co-workers.[105] 571 
 572 
The PK and PD parameters of the model were inferred from the literature and calibrated by 573 
measurements of TXB2, which represents the COX-1 activity in peripheral platelets, in 17 healthy 574 
subjects and 24 patients with essential thrombocythemia (ET).[105] The model was able to reproduce 575 
both the mean TXB2 inhibition time in healthy patients and the reduced inhibition of TXB2 seen in 576 
patients with ET. Thus, this mechanistic PK/PD model may helpful to customize aspirin regimens under 577 
conditions of altered megakaryopoiesis. 578 
 579 
In addition to the dissociation between PK (short half-life of elimination) and PD (long response period) 580 
demonstrated by the models described above, the dose-response relationship for platelet inhibition 581 
by aspirin is flat. Feldman and co-workers[101] demonstrated that even with a 10-fold increase in dose 582 
of aspirin, only a two-fold increase in response (inhibition of TXB2) was observed. Since doses of 81 583 
and 325 mg of ASA are not significantly different with regard to this clinical response, applying a  low 584 
dose of aspirin to prevent platelet aggregation is justified.[101] 585 
In summary, mechanistic models of the pharmacodynamic action of aspirin on platelets appear to be 586 
useful for customizing the prevention of thrombus formation and for designing clinical trials in special 587 
patient populations e.g. the elderly, pregnant women, children, obese patients, etc. Indeed, regulatory 588 
authorities are increasingly relying on and encouraging the use of modeling and simulation to forecast 589 
changes in PK and PD in rare diseases and in special populations of patients in whom it is challenging 590 
to perform clinical trials. 591 
3.2.3 Exemestane 592 
 593 
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Exemestane, an irreversible aromatase type I (Ar type I) inhibitor for the treatment of advanced breast 594 
cancer of postmenopausal women, provides a further, interesting example of irreversible binding and 595 
biological target inactivation.  596 
 597 
In an open, three-period, randomized, crossover study of twelve healthy post-menopausal women 598 
Valle et al. investigated the effects of formulation (suspension versus tablet) and administration of 599 
food (i.e. fasted versus fed) on the pharmacokinetics and pharmacodynamics of exemestane. As had 600 
already been demonstrated by previous clinical trials, oral administration of exemestane (25 mg/day) 601 
inactivates peripheral aromatase, leading to a 85-95% decrease in basal plasma estrone, estradiol and 602 
estrone sulphate (EIS) concentrations in post-menopausal women with advanced breast cancer. 603 
[106],[107],[108] First, population pharmacokinetic models, consisting of a mono- or bi- exponential 604 
absorption and three compartment distribution function, with empirical Bayesian estimates for each 605 
individual were developed. Absorption lag times were determined for both absorption models. An 606 
inhibitory (type I) indirect response pharmacodynamic model (see more details in section 4.1), in which 607 
synthesis and elimination of EIS (which is indirectly related to aromatase activity) are governed by zero- 608 
and first-order rate constants, respectively, was implemented to describe the dissociation between 609 
plasma concentrations and the observed effect: 610 
𝑑𝐶𝐸𝐼𝑆
𝑑𝑡
= 𝑘𝑠 − 𝑘𝑜 · 𝐶𝐸𝐼𝑆     (18) 611 
𝑑𝐶𝐸𝐼𝑆
𝑑𝑡
= 𝑘𝑠 · (
𝐶𝛾
𝐶𝛾 + 𝐼𝐶50
𝛾 ) − 𝑘𝑜 · 𝐶𝐸𝐼𝑆   𝐶𝐸𝐼𝑆(0) = 𝐶𝐸𝐼𝑆 0    (19) 612 
where 𝐶𝐸𝐼𝑆 is the plasma concentration of estrone sulphate, 𝑘𝑠 is the zero order rate constant for 613 
synthesis and 𝑘𝑜 is the first-order rate constant for elimination, 𝐶
𝛾 is the exemestane plasma 614 
concentration, 𝐼𝐶50 represents the exemestane plasma concentration at which 50% of inhibition is 615 
achieved and γ is the Hill-coefficient. This semi-empirical, non-linear mixed-effect modeling approach 616 
fitted the data adequately.  617 
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A more mechanistic model, incorporating the irreversible aromatase inactivation by exemestane, was 618 
also applied. In this model the aromatase concentration, Ar, is assumed to be the system variable 619 
controlling the rate of synthesis of EIS. The production and elimination rate of aromatase is in turn 620 
governed by a zero-order (𝑘𝑠𝑒) and first-order (𝑘𝑜𝑒) rate constant, respectively. The irreversible 621 
inhibition of aromatase by exemestane is characterized by an increase in the elimination of aromatase 622 
and represented by a second-order rate constant 𝑘𝑖. Assuming that the concentration of EIS precursor 623 
is constant and the concentration of aromatase is known, the model is fully identifiable. The rate of 624 
concentration changes of EIS and Ar are defined by the equations:  625 
𝑑𝐶𝐸𝐼𝑆
𝑑𝑡
= 𝑘𝑠 · 𝐴𝑟 − 𝑘𝑜 · 𝐶𝐸𝐼𝑆     𝐶𝐸𝐼𝑆(0) = 𝐶𝐸𝐼𝑆 0     (20) 626 
𝑑𝐴𝑟
𝑑𝑡
= 𝑘𝑠𝑒 − 𝑘𝑜𝑒 · 𝐴𝑟 − 𝑘𝑖 · 𝐶𝐸𝐼𝑆 · 𝐴𝑟    𝐴𝑟(0) = 𝐴𝑟0     (21) 627 
 628 
where 𝐴𝑟0 is the baseline concentration of aromatase. 629 
 630 
The adoption of a more physiological relevant mechanism of action in the model was expected to 631 
provide better results. Nevertheless, the goodness of fit was not significantly improved over the type 632 
I indirect response model. Despite being semi-empirical, the type I indirect-response model was able 633 
to predict the drug effect in different scenarios (i.e. doses, dosage regimens), providing an external 634 
validation. In a sense, the initial, indirect response type I model could be considered as a “collapsed” 635 
form of the mechanism-based model, under the assumptions that Hill-coefficient is equal to one (γ=1) 636 
and that the aromatase dynamics equation is solved at equilibrium and then substituted in the EIS 637 
equation. These assumptions appear to be justified in the case of exemestane, since the 638 
pharmacodynamic parameters do not change significantly in the data range studied and a value of Hill-639 
coefficient 1.75 (γ=1.75) has been reported. Hence, a relatively flat dose-response is implied. 640 
 641 
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An almost 4-fold increase in the absorption rate of exemestane when administered as a suspension as 642 
compared to a tablet was detected, while food intake decreased the absorption rate. Interestingly, 643 
these differences were mitigated in terms of pharmacodynamic response such that the maximum 644 
effect and time to maximum effect were not significantly different among treatment groups. The 645 
authors concluded that even large differences in pharmacokinetics arising from formulation or 646 
administration with food were not translated to a meaningful difference in pharmacodynamics. 647 
 648 
The example of exemestane is interesting for two main reasons: a) it illustrates that a mechanism-649 
based model of irreversible pharmacodynamics can be transformed, depending on data availability or 650 
fast equilibration, to a simplified, “collapsed” model, without influencing the outcome appreciably, 651 
and b) observed differences in absorption patterns and food effects are not always clinically relevant, 652 
especially when there is a long delay between plasma levels and the elicited drug response. Again, 653 
these findings support the consideration of pharmacodynamics as well as pharmacokinetics when 654 
determining whether two drug products or two dosing scenarios are therapeutically equivalent. 655 
 656 
4 Indirect response and feedback control models 657 
 658 
4.1 Overview 659 
 660 
Most pharmacological targets are subject to homeostatic mechanisms, characterized by continuous 661 
degradation on the one hand and re-synthesis of one or more biomarkers (e.g. enzymes, antibodies, 662 
circulating proteins or inflammation factors) to compensate for elimination on the other hand, which 663 
balance each other to maintain a stable steady-state. This is often referred to as the turnover process. 664 
Some drugs elicit their action by perturbing the steady-state, resulting in a temporary or a more 665 
permanent change in the marker value. Such mechanisms of actions, which do not affect the response 666 
itself but rather influence the turnover process, are inherently indirect and the models describing their 667 
effect-time course are usually referred to as turnover or indirect response models. These models 668 
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typically exhibit a delay between the drug concentration-time and response-time profiles. The 669 
amplitude of the response and the extent of the time delay are dependent on the turnover rates 670 
(synthesis and degradation) of the pharmacological target as well as the magnitude of the effect. 671 
4.1.1 “Basic” and “extended basic” indirect response models 672 
 673 
Nagashima et al.[109] were the first to implement an indirect response model, which was used to explain 674 
the anticoagulant effect of warfarin on the activity of the prothrombin complex. In 1993, Dayneka et 675 
al.[110] introduced four basic mathematical models describing the indirect pharmacological processes, 676 
according to which the production and loss of the response, R, are governed by zero- and first-order 677 
rate constants, kin and kout, respectively. The drug can inhibit or stimulate the synthesis and/or the 678 
elimination process as follows:  679 
Model I (inhibition of kin):  680 
𝑑𝑅
𝑑𝑡
= 𝑘𝑖𝑛 · (1 −
𝐼𝑚𝑎𝑥 · 𝐶
𝐶 + 𝐼𝐶50
) − 𝑘𝑜𝑢𝑡 · 𝑅,   𝑅(0) = 𝑅0      (22)   681 
Model II (inhibition of kout): 682 
𝑑𝑅
𝑑𝑡
= 𝑘𝑖𝑛 − 𝑘𝑜𝑢𝑡 · (1 −
𝐼𝑚𝑎𝑥 · 𝐶
𝐶 + 𝐼𝐶50
) · 𝑅,   𝑅(0) = 𝑅0      (23)   683 
Model III (stimulation of kin): 684 
𝑑𝑅
𝑑𝑡
= 𝑘𝑖𝑛 · (1 +
𝐸𝑚𝑎𝑥 · 𝐶
𝐶 + 𝐸𝐶50
) − 𝑘𝑜𝑢𝑡 · 𝑅,   𝑅(0) = 𝑅0      (24) 685 
Model IV (stimulation of kout):  686 
𝑑𝑅
𝑑𝑡
= 𝑘𝑖𝑛 − 𝑘𝑜𝑢𝑡 · (1 +
𝐸𝑚𝑎𝑥𝐶
𝐶 + 𝐸𝐶50
) · 𝑅,   𝑅(0) = 𝑅0      (25) 687 
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where 𝑘𝑖𝑛, 𝑘𝑜𝑢𝑡 are the zero order production and first order elimination rate constants, C is the drug 688 
plasma concentration, and 𝐸𝐶50 and 𝐼𝐶50 represent the drug plasma concentrations achieving 50% of 689 
the maximum stimulating, 𝐸𝑚𝑎𝑥, and inhibitory, 𝐼𝑚𝑎𝑥, effects, respectively. 690 
These four basic models, which are illustrated in Figure 7, have been applied extensively and some 691 
examples have been summarized by Jusko and Ko.[4] The inhibition of basophil trafficking by 692 
methylprednisolone and the furosemide-mediated inhibition of water reabsorption from the tubules 693 
and collecting duct were assessed by Model I and II, respectively, while the stimulation of the cyclic 694 
adenosine monophosphate (cAMP)-induced bronchodilation by the β-adrenergic receptor agonist 695 
terbutaline was described by Model III. In a further example, it was shown that the increase in cAMP 696 
by terbutaline activates the cellular membrane sodium-potassium pump, resulting in an increase of 697 
efflux of potassium ions from the plasma into cells, an effect that can be described with Model IV. 698 
These basic turnover models can be modified and/or extended to account for more complex 699 
physiological processes such as time-dependent production (kin(t)),[111] the rate of loss of cells 700 
according to their lifespan[112],[113],[114] and capacity limited processes such as nonlinear synthesis and 701 
degradation functions.[115] Further, many physiological processes such as secretion of hormones and 702 
gastric acid, gene expression, cardiac output and blood pressure are known to be subject to circadian 703 
rhythms, which might influence the pharmacokinetics and pharmacodynamics of various 704 
drugs.[116],[117],[118] Symmetric circadian rhythms have been described by trigonometric functions, such 705 
as the cosine model introduced by Lew et al.,[119] whereas asymmetric circadian rhythms have been 706 
modelled with the addition of exponential, dual cosine or harmonic functions.[120],[111] The detailed 707 
mathematical formalism around these functions has been summarized by Krzyzanski.[121] 708 
 709 
4.1.2 Signal transduction and feedback control indirect response models 710 
 711 
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When a sequence of events takes place between receptor binding or activation and the observable 712 
effect, this is referred to as signal transduction and can involve signaling cascades, activation or 713 
inhibition of secondary messengers, gene up- or down-regulation and mRNA transcription to 714 
functional proteins. By definition, every transduction process has two inherent attributes: the 715 
transformation of the original signal and the introduction of a time-delay.[122],[123] Depending on the 716 
experimental time-scale, the time delay might or might not be discernable and in the latter case the 717 
response is described by a transduction model with no delay, for example in the operational model of 718 
agonism introduced by Black and Leff.[124] This model has been applied to describe the 719 
pharmacokinetic/pharmacodynamic relationships of A1 adenosine, μ-opioid and 5-HT1A receptor 720 
agonists.[125],[126],[127],[128],[129] However, in other cases the time delay produced by the transduction 721 
process is significant and the mathematical models need to be adjusted accordingly. The most common 722 
approach is the so-called transit compartment model (Fig. 8), which has been applied to the modeling 723 
of the genomic effects of corticosteroids, in this case known as the 5th generation model for 724 
corticosteroids, as well as myelosuppression and hematologic toxicity in cancer 725 
chemotherapy.[130],[131],[132],[133] 726 
Most physiological processes are subject to feedback control and belong to the so-called 727 
autoregulation systems. The pharmacokinetic/pharmacodynamic (PK/PD) models that do not address 728 
these auto-regulatory mechanisms fail to provide a complete insight of the drug-exposure relationship 729 
and it has been shown that this can lead to underestimation of the drug’s potency.[123] The feedback 730 
control indirect response (FC IDR) models (see Figure 9) usually incorporate terms proportional to the 731 
error signal itself, the integral and the derivative of the error signal in linear and, less commonly, in 732 
nonlinear combinations. There are also FC IDR models which include an additional state, the 733 
“moderator” state, which feeds back to alter the synthesis or turnover of the response.[134] Numerous 734 
applications of PK/PD models incorporating feedback regulation mechanisms have been published in 735 
the literature.[132],[135],[136] The example of (S)-citalopram, a widely used selective serotonin receptor 736 
inhibitor (SSRI), is presented in detail in section 4.3. 737 
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4.2 Applications and case examples 738 
 739 
4.2.1 Ibuprofen: antipyretic response  740 
 741 
As mentioned in section 2.2.2, the antipyretic effect of ibuprofen resulting from the inhibition of 742 
prostaglandin synthesis has been investigated in numerous clinical studies and an indirect response 743 
model has been applied to fit the reported pharmacodynamic data. In a single-dose, placebo-744 
controlled, double-blind and parallel-group trial by Walson et al.,[137] the safety, efficacy, tolerability 745 
and dose-effect relationships of ibuprofen products, formulated as a suspension at doses of 5 mg/kg 746 
and 10 mg/kg to treat febrile children, were compared to liquid formulations of acetaminophen. The 747 
patients (N=127) were split into groups according to their initial temperature and on whether 748 
antibiotics were being administered concurrently. A positive dose-response relationship between 749 
ibuprofen suspension 5 mg/kg and 10 mg/kg in the higher temperature (102.6-104°F), non-antibiotic 750 
group was demonstrated, whereas in the lower temperature group (101-102.5°F) both doses were 751 
equally effective. However, the authors pointed out that the plasma levels necessary for maximum 752 
effective antipyresis of ibuprofen (approximately 10 mg/L) are achievable at doses even less than 5 753 
mg/kg, implying a ceiling effect in the antipyretic response at doses of 5 mg/kg or higher. 754 
 Similar results in 178 children were observed by Wilson et al.[138] In a single-dose, placebo-controlled 755 
study, during which age and initial temperature were considered as co-variates, both the 5 and 10 756 
mg/kg doses were significantly superior to placebo, but not different from each other in terms of 757 
maximum reduction in temperature. However, it was concluded, based on the temperature at 6 hours 758 
after administration, the change of temperature from the baseline value and the percentage of 759 
efficacy, that the 10 mg/kg dose was more effective. The effect of the age and the initial temperature 760 
value on the magnitude of the pharmacological action was also emphasized.   761 
In a double-blind, randomized, single-dose study of 5 and 10 mg/kg ibuprofen to treat febrile children 762 
(N=153) Brown et al.[139] noted a dissociation between tmax and time of maximum temperature 763 
decrease and found no correlation between the extent of temperature change and plasma levels at 764 
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tR,max or 6 hours post-administration. Further, there was no evidence that pretreatment with 765 
antibiotics, race or gender influenced the antipyretic effect. By contrast, age and initial temperature 766 
were shown to be co-variates. Interestingly, after compartmental pharmacokinetic analysis, only the 767 
pharmacodynamic, but not the pharmacokinetic parameters related to absorption (Cmax, tmax) and 768 
elimination (kel, t1/2), were affected by the age of the child. In a subsequent paper, Brown et al. [140] 769 
implemented an effect-compartment model coupled with a sigmoid Emax pharmacodynamic model to 770 
describe the antipyretic effect of ibuprofen in children and further elaborated the model by adding a 771 
linear and/or sinusoidal cyclic function for the decrease in temperature as co-variates to fit their own 772 
as well as previously reported data [138]. Values of the estimated sigmoidicity factor (γ) were 3.97 ± 0.58 773 
and 4.27 ± 0.63 for ibuprofen 5 mg/kg and 10 mg/kg, respectively, implying that the dose-response 774 
relationship for antipyresis in children might be steeper than for dental pain relief in adults.  775 
Troconiz et al.[47] reported a temporal disconnection between tmax after administration to febrile 776 
children of 7 mg/kg ibuprofen as a suspension or as effervescent granules dosed at 200 or 400 mg (0.5 777 
for the suspension and 1.9 hours for the effervescent granules) and time of maximum decrease in body 778 
temperature (3 hours in both cases), suggesting that the formulation and its pharmacokinetic behavior 779 
has little impact on the antipyretic effect of ibuprofen. The antipyretic response of non-steroidal anti-780 
inflammatory drugs (NSAIDs) has been attributed to their ability to inhibit the synthetic pathway of 781 
prostaglandins, particularly of prostaglandin E2 (PGE2), via an indirect mechanism.[141] The following 782 
equation was derived to describe the pharmacodynamics of antipyresis by this mechanism: 783 
𝑑𝑇
𝑑𝑡
= 𝑘𝑠𝑦𝑛 · (1 − 𝐸max ·
𝐶𝛾
𝐶𝛾 + 𝐸𝐶50
𝛾 ) − 𝑘𝑜𝑢𝑡 · 𝑇        (26) 784 
where 𝑑𝑇 𝑑𝑡⁄  represents the rate of body temperature change with time, 𝑘𝑠𝑦𝑛 and 𝑘𝑜𝑢𝑡 are the zero-785 
order and first-order rate constants for synthesis and degradation of the inflammation mediator (i.e. 786 
PGE2), respectively, 𝑇 is the body temperature, 𝐸max is the maximum antipyretic effect, 𝐸𝐶50 is the 787 
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drug plasma concentration (𝐶) required to achieve half of the maximum effect and 𝛾 is the sigmoidicity 788 
factor. 789 
The proposed pharmacokinetic-pharmacodynamic model fitted the antipyretic profiles well. The 790 
estimated 𝐸𝐶50 and 𝑘𝑜𝑢𝑡 parameters were in agreement with those previously reported by Garg and 791 
Jusko (6.18 versus 10.2 mg/L for 𝐸𝐶50 and 1.17 versus 0.89 h
-1 for 𝑘𝑜𝑢𝑡), who had also applied an 792 
indirect response model.[142] The sigmoidicity factor was calculated to be 2.71 ± 0.18, suggesting a 793 
relatively flat dose-response curve. In contrast to previous studies, however, age and initial 794 
temperature did not elicit covariate effects. [138],[143]  795 
Based solely on the differences in Cmax and tmax between the suspension and the effervescent granule 796 
formulations, a delayed onset of drug action would be expected for the effervescent granules. 797 
Nevertheless, the maximum antipyretic effect was similar and occurred at the same time for both 798 
formulations. Importantly, an almost identical mean effect time course of 200 and 400mg of Ibuprofen 799 
effervescent granules in febrile children was observed, implying that at least for this formulation there 800 
was no significant clinical benefit with a dose increase (Fig. 10). Therefore, the authors concluded that 801 
the formulation-dependent pharmacokinetic differences are mitigated by the response mechanism, 802 
leading to similar pharmacodynamic responses for both formulations at both doses in febrile children. 803 
Using a verified PBPK/PD model Cristofoletti and Dressman simulated the antipyretic response with 804 
virtual trials of 2, 5, 7 or 10 mg/kg dosing of Ibuprofen suspension to 100 febrile children per trial in 805 
the age range of 2-11 years.[58] In terms of maximum decrease in temperature from the baseline value, 806 
the 5, 7 and 10 mg/kg doses were proven to be significantly superior to 2 mg/kg but not statistically 807 
different from one another. A rather flat dose-response curve (with EC50≈6.18 mg/L) was confirmed 808 
for the antipyretic effect in children. Under the assumption that the 7 and 10 mg/kg dose represent 809 
the test and reference products, respectively, the test product would be bioinequivalent to the 810 
reference in terms of Cmax and AUC ratios (Cmax,T/Cmax,R and AUCmax,T/AUCmax,R around 0.7), but still 811 
therapeutically equivalent in children. This conclusion is supported by the data from Troconiz et al.[47], 812 
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whose clinical trial demonstrated superimposable antipyretic profiles between ibuprofen suspension 813 
7 mg/kg and effervescent granules 400 mg (normalized by children mean body weight as 11.8 mg/kg) 814 
after administration to febrile children.                                 815 
4.2.2 Rosuvastatin 816 
 817 
Of the currently available 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) 818 
inhibitors, rosuvastatin is one of the most effective at lowering the low density lipoprotein (LDL) 819 
cholesterol. Mevalonic acid synthesis, which takes place in the liver, is catalyzed by HMG-CoA 820 
reductase and is the first irreversible stage of the cholesterol biosynthetic pathway.[144],[145],[146]  821 
A pharmacokinetic/pharmacodynamic model was developed to predict the response of rosuvastatin 822 
to different dosage regimens and identify differences in response between morning (at 07:00 a.m.) 823 
and evening (at 06:00 p.m.) administration. For this purpose, Aoyama et al.[147] used a two-824 
compartment pharmacokinetic model with first order absorption and elimination from the central 825 
compartment, which was then linked to a modified inhibitory indirect response pharmacodynamic 826 
model describing the plasma concentrations of mevalonic acid (MVA). The model was further extended 827 
by incorporating a time-dependent periodic function in the zero-order synthesis rate constant of 828 
mevalonic acid to account for the circadian rhythm, as introduced by Krzyzanski et al.[148],[149] The model 829 
is presented in Figure 11 and described by the following equations:  830 
𝑑𝑅
𝑑𝑡
= 𝑘𝑖𝑛 · (1 −
𝐶𝑝
𝛾
𝐶𝑝
𝛾 + 𝐼𝐶𝑝50
𝛾 ) − 𝑘𝑜𝑢𝑡 · 𝑅     (27)    831 
where R is the response, 𝑘𝑖𝑛 is the time-dependent zero order rate constant for the increase in plasma 832 
MVA concentration, 𝑘𝑜𝑢𝑡  is the first order rate constant for the decrease in plasma MVA 833 
concentration, 𝐶𝑝 represents the plasma concentration of rosuvastatin, 𝐼𝐶𝑝50 is the plasma 834 
concentration at which 𝑘𝑖𝑛 is reduced 50% and 𝛾 is the sigmoidicity factor. The time-dependent 𝑘𝑖𝑛 to 835 
account for the circadian rhythm is defined as follows 836 
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𝑘𝑖𝑛 =  𝑘𝑚 + 𝑘𝑎𝑚𝑝 · cos(2 · 𝜋(𝑡 − 𝑡𝑧) 24⁄ )    (28) 837 
where 𝑘𝑚 and 𝑘𝑎𝑚𝑝 represent the mean MVA synthesis and its amplitude rate constants, respectively, 838 
and 𝑡𝑧 is the acrophase time, during which MVA is synthesized at the maximum rate. The following 839 
function to describe the circadian rhythm of 𝑘𝑚  was proposed by Krzyzanski et al.
[148]: 840 
𝑘𝑚 =  𝑘𝑜𝑢𝑡 · 𝐼𝐶 −
𝑘𝑎𝑚𝑝 · 𝑘𝑜𝑢𝑡
2
𝑘𝑜𝑢𝑡
2 + (2𝜋 24⁄ )2
· [cos (
2 · 𝜋 · (𝑡𝑧)
24
) − (
2 · 𝜋
24 · 𝑘𝑜𝑢𝑡
) · 𝑠𝑖𝑛 (
2 · 𝜋 · (𝑡𝑧)
24
)]    (29) 841 
where IC is the initial plasma MVA concentration measured at 6 a.m., set to 4.32 ng/ml. 842 
Application of the time course of rosuvastatin and mevalonic acid plasma concentration to the model 843 
enabled an adequate prediction of the clinical data reported by Martin et al.[150] A higher reduction 844 
ratio of 7.7% in the area under the plasma MVA concentration–time curves over 24 hours at steady 845 
state (AUEC0-24) was observed after administration in the evening. Furthermore, sensitivity analysis on 846 
the pharmacokinetic parameters showed that changes in the pharmacokinetics have a greater effect 847 
on the AUEC0-24 reduction ratio after morning than after evening administration. This was attributed 848 
to the circadian rhythm, with the acrophase time estimated to be 15.5 hours. The authors concluded 849 
that evening administration of rosuvastatin might be useful in clinical practice.[147] The main limitation 850 
of the model is that it is based only on the mean plasma pharmacokinetic and pharmacodynamic data. 851 
Therefore, it does not address the concentration at the effect site, which is the liver and not the 852 
plasma, or the inter-subject variability. Most importantly, the use of only one mean PK/PD data set 853 
raises questions about the identifiability of the estimated parameters and caution should be exercised 854 
in drawing conclusions about the validity of this model. 855 
Since the liver is the effect site for the statins, uptake into the liver is an important factor in their 856 
efficacy. Multiple transporters of the family of the organic anion transporting polypeptide (OATP) 857 
family are abundant in the liver, facilitating the active hepatic uptake of endogenous substances and 858 
xenobiotics, including statins, from sinusoidal blood.[151],[152],[153],[154],[155] Rosuvastatin is a substrate of 859 
the organic anion transporting polypeptide 1B1, 1B2, 1B3, 1A2 and the sodium-dependent 860 
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taurocholate co-transporting polypeptide.[151],[156] The expression of OATP1B1 on the sinusoidal 861 
membrane of human hepatocytes is encoded by the gene SLCO1B1, which is subjected to single-862 
nucleotide polymorphisms (SNPs). As already demonstrated for paravastatin, pitavastatin and 863 
simvastatin, such polymorphisms are associated with reduced OATP1B1 in vitro activity and markedly 864 
increased plasma concentrations.[157],[158],[159],[160],[161] Pasanen et al.[158] investigated the effect of 865 
SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin, after oral 866 
administration in 32 healthy volunteers, with the following genotypes: SLCO1B1 c.521CC (n=4), 867 
SLCO1B1 c.521CT (n=12), SLCO1B1 c.521TT (wild type, n=16). Significant increases in the AUC0-48 h and 868 
Cmax (65% and 79%, respectively) in SLCO1B1 c.521CC subjects compared to the reference genotype, 869 
SLCO1B1 c.521TT, were observed. By contrast, increases in the AUC0-48 h (144% increase), but not the 870 
Cmax, were reported after administration of atorvastatin. This study implies that the reduced OATP1B1-871 
mediated hepatic uptake of rosuvastatin due to SLCO1B1 polymorphism results in an increased risk of 872 
a reduced cholesterol-lowering effect as well as adverse effects such as myopathy and/or 873 
rhabdomyolysis. 874 
Based on the model of Aoyama et al.,[147] a full PBPK/PD model was built in the SimCyp Simulator® by 875 
Rose et al.[162] to investigate the impact of polymorphic hepatic uptake (OATP1A1, OATP1B4) and efflux 876 
transposers (BcRP, MRP2) on the disposition, pharmacologic and toxic effects of rosuvastatin. First, 877 
plasma concentrations were linked to the cholesterol-lowering effect of rosuvastatin, according to the 878 
plasma AUC of MVA. The simulations performed with the PBPK/PD model showed a large increase in 879 
the mean plasma AUC infinity (AUC∞)  of rosuvastatin by 63% and 111% for the SLCO1B1 c.521CT and 880 
SLCO1B1 c.521CC, respectively, compared to the wild type (SLCO1B1 c.521TT). Similarly, a significant 881 
increase in MVA plasma AUC of 30% and 35% for the same genotypes was observed. However, the 882 
hepatic unbound intracellular water concentration (CuIW) of rosuvastatin, which was predicted by a 883 
permeability limited liver model, was considered to be a more relevant driver of its pharmacodynamic 884 
effect. Interestingly, only a slight decrease in CuIW based AUC∞ of 5.7% and 9.6%, with a parallel 885 
decrease in MVA plasma AUC of 3.1% and 5.8% were reported for the heterozygote and homozygote, 886 
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respectively. The latter findings are in agreement with a number of studies showing that OATP1B1 887 
c.521T>C SNP has either no or only a slight effect on the cholesterol-lowering response to 888 
statins,[163],[164],[165] and that when plasma concentrations were used as the input, the results were 889 
misleading. 890 
With regard to toxic effects, the effect of genetic polymorphism on rosuvastatin-mediated myopathy 891 
was investigated by prediction of muscle concentrations using a perfusion-limited model. A strong 892 
correlation between plasma concentrations and the risk of muscle-related adverse effects was 893 
observed. Thus, in contrast to the results for the cholesterol-lowering effect of rosuvastatin, the 894 
plasma concentration appears to be a good surrogate for the concentration at the muscle when 895 
assessing the risk of statin-induced muscle toxicity in individuals with polymorphic hepatic uptake 896 
transporter activity. This result was also in agreement with an already published study.[166] 897 
High inter-individual variability among the different genotypes, limited availability of accurate in vitro 898 
data and/or published clinical studies at different dose levels as well as incomplete understanding of 899 
the impact of transporters on pharmacokinetics and/or pharmacodynamics, are some of the 900 
limitations which restrict the robustness of the models for rosuvastatin and their confidence in 901 
simulating different clinical scenarios. Despite these limitations, rosuvastatin serves as a useful case 902 
example to demonstrate the potential of linking PBPK with PD model to enhance physiological 903 
understanding and improve the ability to assess the impact of transporters on the pharmacologic 904 
and/or toxic response. Of particular importance was the finding that, in some instances, parameters 905 
other than the plasma concentration are appropriate indicators of the therapeutic and/or toxic effect.  906 
This example illustrates that implementation of (PB)PK/PD models (even on an exploratory basis) can 907 
provide valuable information during clinical drug development and significantly contribute to the 908 
clinical ramifications of genetic polymorphism and facilitate an optimal dosing regimen. 909 
4.2.3 Escitalopram 910 
 911 
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Selective serotonin reuptake inhibitors (SSRIs), such as escitalopram, block the neuronal reuptake of 912 
serotonin (5-HT), resulting in increased neurotransmitter concentration at the terminal and somato-913 
dendritic areas. However, the auto-receptors 5-HT1A and 5-HT1B, which regulate the 5-HT release from 914 
neurons by negative feedback control, are also situated at the terminal and somato-dendritic neuronal 915 
parts, respectively (Fig. 12).[167] Intracerebral microdialysis can be used to measure the extracellular 916 
concentration of 5-HT and thus its concentration at the site of action.[168],[169]  917 
Bundgaard et al.[170] developed an indirect response PK/PD model for escitalopram, including a 918 
moderator state (tolerance model) to account for the auto-inhibitory feedback. For this purpose, 919 
different doses of escitalopram were administered intravenously at a constant infusion rate over 60 920 
minutes in four groups (vehicle, 2.5, 5 and 10 mg/kg) of six male Sprague-Dawley rats and the response 921 
was expressed as the change in extracellular 5-HT concentration. A two-compartment 922 
pharmacokinetic model with first order elimination from the main compartment was used to fit the 923 
individual mean unbound plasma concentration-time profiles for each dose group and the predicted 924 
profiles were used as the input to drive the pharmacodynamic model. A type II basic indirect response 925 
model was implemented to describe the inhibition of 5-HT reuptake. In this model, the increase in the 926 
response, R, over the baseline value R0, feeds back to the moderator compartment and stimulates the 927 
production of the moderator, M. As a simplifying approximation, the rates in and out of M are 928 
described by a first-order rate constant ktol. An increase in M induces a negative feedback on the 929 
generation of the response and thus enables the baseline value to be reestablished. The model is 930 
illustrated in Figure 13 and described by the following equations:  931 
𝑑𝑅
𝑑𝑡
=
𝑘𝑖𝑛
𝑀
− 𝑘𝑜𝑢𝑡 · 𝑅 · 𝐼(𝐶𝑝)    (30) 932 
𝑑𝑀
𝑑𝑡
= 𝑘𝑡𝑜𝑙 · 𝑅 − 𝑘𝑡𝑜𝑙 · 𝑀      (31) 933 
𝐼(𝐶𝑝) = 1 −
𝐼𝑚𝑎𝑥 · 𝐶𝑝
𝑛
𝐼𝐶50
𝑛 + 𝐶𝑝
𝑛      (32) 934 
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where R, M and Cp represent the response, the moderator and the escitalopram unbound plasma 935 
concentration respectively, Imax, IC50 and n are the maximum inhibitory effect, the potency and 936 
sigmoidicity factor respectively, and 𝑘𝑖𝑛, 𝑘𝑜𝑢𝑡 and 𝑘𝑡𝑜𝑙 represent the turnover rate, fractional turnover 937 
rate and feedback rate constants, respectively (see Fig.13). By setting equations 30 and 31 equal to 938 
zero, the initial baseline conditions are obtained:  939 
𝑘𝑖𝑛 = 𝑘𝑜𝑢𝑡 · 𝑅0
2    (33) 940 
𝑅0 = 𝑀0 = √
𝑘𝑖𝑛
𝑘𝑜𝑢𝑡
  (34) 941 
The feedback control model fitted the response-time data well. Between unbound plasma 942 
concentration and 5-HT response, a distinct time-delay was observed for all doses, leading to a 943 
counter-clockwise hysteresis loop. The development of tolerance was confirmed by the fact that the 944 
terminal phases of the hysteresis loops were not superimposable as a function of dose: the higher dose 945 
groups exhibited a lower response at the same concentration. Based on one-way analysis of variance 946 
(ANOVA) and post hoc analysis, maximal increases in 5-HT extracellular levels reached 337%, 424% and 947 
456% of the baseline and the levels remained elevated for 135, 175 and 235 minutes at the 2.5, 5 and 948 
10 mg/kg doses, respectively. Despite the significant differences in plasma concentrations, the basal 949 
response value was recovered within 360 min following the administration of all tested doses. In fact, 950 
neither the duration nor the magnitude of the response increased when the dose was increased from 951 
5 to 10 mg/kg. These findings are in agreement with previous studies in rats, in which increasing the 952 
dose of escitalopram exhibited a ceiling effect in the extracellular levels of 5-HT in the frontal cortex, 953 
as measured by microdialysis.[171],[172] 954 
The results from this study established the high potency (IC50= 4.4 μg/L) of escitalopram, with almost 955 
complete (Imax= 0.9) inhibition of reuptake. A fast neuronal 5-HT reuptake with a half-life of less than 5 956 
minutes (𝑡1
2⁄ 𝑘𝑜𝑢𝑡
) was reported, whereas the half-life for the development of tolerance,  𝑡1
2⁄ 𝑘𝑡𝑜𝑙
 was 957 
estimated at 10 hours. The importance of incorporating a moderator state to account for the 958 
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physiological homeostatic autoregulation mechanisms was demonstrated by comparison of the 959 
pharmacodynamic parameters of this more mechanistic model with the conventional effect-960 
compartment model. The effect-compartment model predicted higher EC50 values at increased doses, 961 
which was inconsistent with the physiological response. In addition, Zhang and D’Argenio[123] used the 962 
same data sets to compare the performance of the basic model II inhibitory model with and without 963 
the addition of proportional and proportional-plus-integral feedback gain. When the feedback was 964 
omitted, the drug’s potency was underestimated, while the model with the proportional-plus-integral 965 
feedback gain performed the best (lowest Akaike information criterion value). 966 
These findings not only highlight the usefulness of implementing feedback control mechanisms in 967 
pharmacodynamic models, but also the importance of assessing the PK/PD at multiple doses. It is 968 
evident that when the autoregulation of the pharmacodynamic response is not taken into account, the 969 
evaluation of in vivo potency can lead to an underestimation of drug’s potency and application of 970 
unnecessarily high doses. Additionally, feedback control models may be useful for the comparison of 971 
the pharmacodynamic behavior among SSRIs, to improve understanding of their antidepressant 972 
effects and as a guide to set effective plasma concentrations in clinical practice. 973 
5 Outlook and concluding remarks 974 
 975 
This review describes the large variety of pharmacokinetic/pharmacodynamic modeling approaches 976 
available to predict dose-concentration-effect relationships and to simulate various clinical scenarios. 977 
Models incorporating a physiological understanding of the underlying mechanism(s) of action of the 978 
drug and progression of disease can serve as powerful tools for exploring and predicting clinical drug 979 
product performance. Provided such models are adequately validated, they can also be implemented 980 
with confidence to drive model-informed decisions during drug development as well as at the 981 
regulatory level.   982 
An even more complete understanding of a drug’s therapeutic value would be possible if dose-983 
concentration-adverse reactions relationships were to be simultaneously established through 984 
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toxicokinetic/toxicodynamic models, so that not only efficacy, but also safety can be evaluated. This is 985 
important, since dose-response curves may differ significantly between the therapeutic and adverse 986 
effects in different patient populations as well as among different indications of the same drug.  987 
A current limitation of mechanistic models is that their complexity often leads to issues of identifiability 988 
and reproducibility of parameters. The commercially available physiologically based pharmacokinetic 989 
models are often implemented with mostly (or only) literature data. In these models the number of 990 
parameters is often far greater than would be required for application of classical compartmental 991 
models and it may be difficult to acquire reliable values for some parameters. The advent of more 992 
sophisticated analytical techniques such as microdialysis will promote a better understanding of the 993 
time profile of drug concentration at the effect site. In the meantime, to ensure maximum quality and 994 
to facilitate the interpretation of PK/PD models, transparency in the parameter values applied in the 995 
model, as well as in the underlying assumptions and the derived equations, together with 996 
harmonization based on good coding practice (GCP), is essential. 997 
Once there is enough confidence in the translatability, estimation and prediction of preclinical and 998 
clinical PK/PD and systems pharmacology models, a move towards linking them with biorelevant in 999 
vitro tools to guarantee therapeutic equivalence will be another key step forward in the drive to link 1000 
the laboratory to the patient, which seems not only promising, but also imminent. Bridging the gap 1001 
between in vitro, in vivo and in silico methods by applying the Quality by Design (QbD) and the 1002 
Biopharmaceutics Risk Assessment Roadmap (BioRAM),[173],[174] will allow pharmaceutical scientists to 1003 
correctly assess the relative impact of formulation, dose and dosing interval during development of 1004 
new drugs.  1005 
For the formulation scientist, modeling and simulation used in this way will assist in the selection of 1006 
the most appropriate dosage form and to set formulation targets, knowing to what extent the 1007 
formulation can be expected to steer the in vivo performance of the drug product. For the clinician, 1008 
the approach helps to identify the dosing strategy which optimizes the efficacy/safety ratio. 1009 
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For the analyst, modeling and simulation can provide guidance in setting clinically relevant dissolution 1010 
specifications, taking into account not only which formulation factors steer the drug plasma 1011 
concentration (critical quality attributes) but also how any differences in these will translate in the 1012 
clinical outcome. In this context, robust PK/PD modeling approaches will play an essential role in 1013 
model-informed drug development.  1014 
Finally, from a regulatory decision-making point of view, a seamless description of the relationship 1015 
between the pharmacokinetic and pharmacodynamic characteristics of a drug together with a 1016 
knowledge of how, and to what extent, formulation and formulation performance can influence the 1017 
PK and PD, provides an excellent, clinically relevant basis for an integrated approach to assessing 1018 
applications for drug approval.  Currently, pharmacodynamics considerations are taken into account 1019 
in the approval of labeling of new drug products, for example, whether taking the drug before vs. after 1020 
a meal will influence efficacy. There is also a thrust towards virtual bioequivalence, for example using 1021 
PBPK modeling to determine whether a change in the dissolution characteristics will impact the plasma 1022 
profile significantly. A logical further step would be to combine these two approaches to optimize the 1023 
approval process. Foreseen is a scenario in which the release testing in the laboratory reflects the 1024 
release in the target patient population(s), the data are combined with verified PBPK models tailored 1025 
to the target population(s) and then translated with PK/PD modeling into a prediction of the clinical 1026 
outcome.  This scenario would not only provide sponsors as well as the regulatory authority with more 1027 
flexibility in the approval procedure, without sacrificing efficacy or safety, but also be a way forward 1028 
to move effectively towards a more personalized medicine concept. 1029 
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